Patent · US Active

Organic compounds

US8420787B2 · kind B2 · utility

0Cited by

3References

4Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Michael Bardroff · Soest, DE
Matthew Edwards · Kennewick, US
Mehmet Kemal Tur · Aachen, DE
Olaf Ratsch · Bogen, DE

Key dates

Filing date	Feb 21, 2007
Grant date	Apr 16, 2013
Priority date	—
Expiry date	Feb 21, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis inflammatory bowel disease, and Hodgkin's lymphoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.